Literature DB >> 21479160

Inhibition of U6 snRNA Transcription by PTEN.

Stephanie Cabarcas1, Kounosuke Watabe, Laura Schramm.   

Abstract

PROBLEM STATEMENT: RNA polymerase III (RNA pol III) is responsible for transcribing many of the small structural RNA molecules involved in RNA processing and protein translation, thereby regulating the growth rate of a cell. RNA pol III transcribes both gene internal (tRNA) and gene external (U6 snRNA) promoters and proper initiation by RNA polymerase III requires the transcription initiation factor TFIIIB. TFIIIB has been shown to be a target of repression by tumor suppressors such as ARF, p53, RB and the RB-related pocket proteins. Also, TFIIIB activity is stimulated by the oncogenes c-Myc and the ERK mitogen-activated protein kinase. Recently, two TFIIIB subunits, BRF1 and BRF2, have been demonstrated to behave as oncogenes, making deregulation of TFIIIB activity and thus RNA pol III transcription an important step in tumor development. PTEN is a commonly mutated tumor suppressor regulating cell growth, proliferation and survival. Thus, we sought to examine the potential role of PTEN in regulating U6 snRNA transcription. APPROACH: We examined the potential for PTEN to regulate U6 snRNA transcription using in vitro RNA pol III luciferase assays, western blotting and deletion analysis in cancer cell lines differing in their PTEN status.
RESULTS: Using breast, cervical, prostate and glioblastoma cancer cells we demonstrate: (1) PTEN inhibition of gene external RNA pol III transcription is cell type specific, (2) PTEN-mediated inhibition of U6 transcription occurs via the C2 lipid-binding domain and (3) PTEN repression of U6 transcription occurs, at least in part, through the TFIIIB subunit BRF2. CONCLUSION/RECOMMENDATIONS: Our data demonstrates that regulation of the U6 snRNA gene by PTEN is mediated, in part by the TFIIIB oncogene BRF2, potentially identifying novel targets for chemotherapeutic drug design.

Entities:  

Year:  2010        PMID: 21479160      PMCID: PMC3071578          DOI: 10.3844/ojbsci.2010.114.125

Source DB:  PubMed          Journal:  Online J Biol Sci


  43 in total

1.  RNA polymerase III transcription factor IIIB is a target for repression by pocket proteins p107 and p130.

Authors:  J E Sutcliffe; C A Cairns; A McLees; S J Allison; K Tosh; R J White
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

Review 2.  Recruitment of RNA polymerase III to its target promoters.

Authors:  Laura Schramm; Nouria Hernandez
Journal:  Genes Dev       Date:  2002-10-15       Impact factor: 11.361

3.  Inhibition of RNA polymerase III transcription by BRCA1.

Authors:  Ingrid Veras; Eliot M Rosen; Laura Schramm
Journal:  J Mol Biol       Date:  2009-02-11       Impact factor: 5.469

4.  Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity.

Authors:  A Hlobilkova; P Guldberg; M Thullberg; J Zeuthen; J Lukas; J Bartek
Journal:  Exp Cell Res       Date:  2000-05-01       Impact factor: 3.905

5.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.

Authors:  Daniel J Freeman; Andrew G Li; Gang Wei; Heng-Hong Li; Nathalie Kertesz; Ralf Lesche; Andrew D Whale; Hilda Martinez-Diaz; Nora Rozengurt; Robert D Cardiff; Xuan Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

Review 6.  Protean PTEN: form and function.

Authors:  Kristin A Waite; Charis Eng
Journal:  Am J Hum Genet       Date:  2002-03-01       Impact factor: 11.025

Review 7.  PTEN: a novel anti-oncogenic function independent of phosphatase activity.

Authors:  Koichi Okumura; Mujun Zhao; Ronald A DePinho; Frank B Furnari; Webster K Cavenee
Journal:  Cell Cycle       Date:  2005-04-21       Impact factor: 4.534

Review 8.  The nuclear affairs of PTEN.

Authors:  Sarah M Planchon; Kristin A Waite; Charis Eng
Journal:  J Cell Sci       Date:  2008-02-01       Impact factor: 5.285

9.  Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain.

Authors:  Leticia Odriozola; Gobind Singh; Thuong Hoang; Andrew M Chan
Journal:  J Biol Chem       Date:  2007-06-12       Impact factor: 5.157

10.  PTEN represses RNA polymerase III-dependent transcription by targeting the TFIIIB complex.

Authors:  Annette Woiwode; Sandra A S Johnson; Shuping Zhong; Cheng Zhang; Robert G Roeder; Martin Teichmann; Deborah L Johnson
Journal:  Mol Cell Biol       Date:  2008-04-07       Impact factor: 4.272

View more
  9 in total

1.  Cell cycle arrest and apoptosis by expression of a novel TPIP (TPIP-C2) cDNA encoding a C2-domain in HEK-293 cells.

Authors:  Rasmi Rekha Mishra; Jitendra Kumar Chaudhary; Pramod C Rath
Journal:  Mol Biol Rep       Date:  2012-02-07       Impact factor: 2.316

2.  Regulation of RNA polymerase III transcription during transformation of human IMR90 fibroblasts with defined genetic elements.

Authors:  Stéphanie Durrieu-Gaillard; Hélène Dumay-Odelot; Galina Boldina; Nicolas J Tourasse; Delphine Allard; Fabrice André; Françoise Macari; Armelle Choquet; Pauline Lagarde; Guillaume Drutel; Thierry Leste-Lasserre; Marion Petitet; Tom Lesluyes; Lydia Lartigue-Faustin; Jean-William Dupuy; Frédéric Chibon; Robert G Roeder; Dominique Joubert; Stéphan Vagner; Martin Teichmann
Journal:  Cell Cycle       Date:  2018-01-22       Impact factor: 4.534

3.  Gender Specific Differences in RNA Polymerase III Transcription.

Authors:  N Diette; J Koo; S Cabarcas-Petroski; L Schramm
Journal:  J Carcinog Mutagen       Date:  2016-01-29

4.  A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool.

Authors:  Lorea Manterola; Elizabeth Guruceaga; Jaime Gállego Pérez-Larraya; Marisol González-Huarriz; Patricia Jauregui; Sonia Tejada; Ricardo Diez-Valle; Victor Segura; Nicolás Samprón; Cristina Barrena; Irune Ruiz; Amaia Agirre; Angel Ayuso; Javier Rodríguez; Alvaro González; Enric Xipell; Ander Matheu; Adolfo López de Munain; Teresa Tuñón; Idoya Zazpe; Jesús García-Foncillas; Sophie Paris; Jean Yves Delattre; Marta M Alonso
Journal:  Neuro Oncol       Date:  2014-01-16       Impact factor: 12.300

5.  A novel human TPIP splice-variant (TPIP-C2) mRNA, expressed in human and mouse tissues, strongly inhibits cell growth in HeLa cells.

Authors:  Rasmi Rekha Mishra; Jitendra Kumar Chaudhary; Gagan Deep Bajaj; Pramod C Rath
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

6.  RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases.

Authors:  Montserrat Puigdelloses; Marisol González-Huárriz; Marc García-Moure; Naiara Martínez-Vélez; Inés Esparragosa Vázquez; Jordi Bruna; Beatriz Zandio; Amaia Agirre; Miguel Marigil; Gregorio Petrirena; Jorge M Nuñez-Córdoba; Sonia Tejada-Solís; Ricardo Díez-Valle; Jaime Gállego-Culleré; Eduardo Martínez-Vila; Ana Patiño-García; Marta M Alonso; Jaime Gállego Pérez-Larraya
Journal:  Neurooncol Adv       Date:  2020-01-31

7.  BDP1 Alterations Correlate with Clinical Outcomes in Breast Cancer.

Authors:  Stephanie Cabarcas-Petroski; Laura Schramm
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

8.  Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein.

Authors:  Jana Koo; Stephanie Cabarcas-Petroski; John L Petrie; Nicole Diette; Robert J White; Laura Schramm
Journal:  BMC Cancer       Date:  2015-11-16       Impact factor: 4.430

9.  A meta-analysis of BRF2 as a prognostic biomarker in invasive breast carcinoma.

Authors:  Stephanie Cabarcas-Petroski; Patricio I Meneses; Laura Schramm
Journal:  BMC Cancer       Date:  2020-11-11       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.